Division of Gynecologic Oncology, University of Brescia, Viale Europa 11, 25123 Brescia, Italy.
Eur J Cancer. 2010 Mar;46(5):944-53. doi: 10.1016/j.ejca.2009.12.019. Epub 2010 Jan 8.
Prognostic factors currently available are insufficient to predict the clinical course of epithelial ovarian cancer (EOC). In a previous microarray study we identified the human trophoblast cell surface antigen Trop-2 as one of the top differentially expressed genes in serous papillary EOCs compared to normal human ovarian surface epithelial (HOSE) short-term cultures. The aim of the present investigation was to analyse Trop-2 expression at mRNA and protein level and to assess its prognostic significance in EOC.
Using quantitative real-time PCR we tested a total of 104 fresh-frozen EOC tissues and 24 HOSE for Trop-2 mRNA expression. Trop-2 protein expression was then examined by immunohistochemistry in matched formalin-fixed paraffin-embedded EOC samples and in 13 normal ovaries. Finally, we correlated Trop-2 expression to EOC conventional clinicopathological features and patient outcomes.
We found a significant Trop-2 mRNA and protein upregulation in EOCs compared to normal controls (p<0.001). Trop-2 protein overexpression was significantly associated with the presence of ascites (p=0.04) and lymph node metastases (p=0.04). By univariate survival analysis, Trop-2 protein overexpression was significantly associated with decreased progression-free (p=0.02) and overall survival (p=0.01). Importantly, Trop-2 protein overexpression was an independent prognostic marker for shortened survival time in multivariate Cox regression analysis (p=0.04, HR=2.35, CI(95%)=1.03-5.34).
Our results indicate, for the first time, that Trop-2 protein overexpression correlates with an aggressive malignant phenotype and may constitute a novel prognostic factor for EOC. The targeting of Trop-2 overexpression by immunotherapeutic strategies may represent an attractive and potentially effective approach in patients harbouring EOC.
目前可用的预后因素不足以预测上皮性卵巢癌(EOC)的临床过程。在之前的微阵列研究中,我们发现人类滋养细胞表面抗原 Trop-2 是与正常人类卵巢表面上皮(HOSE)短期培养相比在浆液性乳头状 EOC 中差异表达最高的基因之一。本研究的目的是分析 Trop-2 在 mRNA 和蛋白质水平的表达,并评估其在 EOC 中的预后意义。
我们使用定量实时 PCR 测试了总共 104 个新鲜冷冻的 EOC 组织和 24 个 HOSE 的 Trop-2 mRNA 表达。然后,通过免疫组织化学在匹配的福尔马林固定石蜡包埋的 EOC 样本和 13 个正常卵巢中检查 Trop-2 蛋白表达。最后,我们将 Trop-2 表达与 EOC 常规临床病理特征和患者结局相关联。
与正常对照组相比,我们发现 EOC 中 Trop-2 mRNA 和蛋白表达显著上调(p<0.001)。Trop-2 蛋白过表达与腹水(p=0.04)和淋巴结转移(p=0.04)的存在显著相关。通过单因素生存分析,Trop-2 蛋白过表达与无进展生存期(p=0.02)和总生存期(p=0.01)缩短显著相关。重要的是,Trop-2 蛋白过表达是多变量 Cox 回归分析中缩短生存时间的独立预后标志物(p=0.04,HR=2.35,CI(95%)=1.03-5.34)。
我们的研究结果首次表明,Trop-2 蛋白过表达与侵袭性恶性表型相关,可能成为 EOC 的新的预后因素。免疫治疗策略靶向 Trop-2 过表达可能代表一种有吸引力且潜在有效的方法,用于治疗患有 EOC 的患者。